The study will be presented by study authors throughout a special press conference.

Active surveillance is apparently safer management technique for prostate cancer patients Four studies evaluating performance, trends and other factors for active surveillance in managing prostate cancer tumor will be presented through the 110th Annual Scientific Conference of the American Urological Association . The study will be presented by study authors throughout a special press conference drug information . Stacy Loeb, MD, assistant professor of urology at NY University, will moderate the program at the Ernest N. Morial Convention Center in New Orleans, LA on, may 16, 2015 at 9 a.m. CT. During active surveillance, prostate malignancy is thoroughly monitored for indications of progression through regular prostate-particular antigen screening, prostate exams, imaging and sometimes repeat biopsies.

Within the strategic agreement, ActiveCare could have exclusive usage of the Vista Therapeutics’ technology in older people market . Mr. Dalton concluded, ‘We are really pleased to possess such a strategic partner as Vista Therapeutics.’.. ActiveCare, Vista Therapeutics announce strategic romantic relationship to build up Nano Biosensors for seniors ActiveCare, Inc. and Vista Therapeutics, Inc. Announced today a strategic relationship to develop Nano Biosensors for ActiveCare’s services and products to be used by the elderly.’ Vista Therapeutics specializes in developing leading nanotechnology.